Sormani MP, Häring DA, Kropshofe H, et al. Blood NfL as a potential endpoint in Phase 2 clinical studies in relapsing-remitting multiple sclerosis. ECTRIMS 2017, #277.
Subklinische manifestatie MS bij asymptomatische familieleden
jun 2017 | Multipele Sclerose